ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Food Hypersensitivity
Hypersensitivity
Psoriasis
Allergic Rhinitis

Eczema trials near Kansas City, KS, USA:

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Enrolling
Eczema Atopic Dermatitis
Eczema, Atopic
Drug: Placebo
Drug: Camoteskimab

Phase 2

Apollo Therapeutics

Saint Joseph, Missouri, United States and 35 other locations

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Phase 3

Lilly
Lilly

Saint Joseph, Missouri, United States of America and 41 other locations

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Active, not recruiting
Atopic Dermatitis Eczema
Drug: Placebo
Drug: ANB032

Phase 2

AnaptysBio
AnaptysBio

Saint Joseph, Missouri, United States and 79 other locations

/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Leawood, Kansas, United States of America and 234 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Overland Park, Kansas, United States and 560 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Shawnee Mission, Kansas, United States and 320 other locations

Locations recently updated

assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Phase 3

AbbVie
AbbVie

Saint Joseph, Missouri, United States of America and 73 other locations

Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

Phase 3

Amgen
Amgen

Leawood, Kansas, United States of America and 499 other locations

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Enrolling
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

Phase 3

Amgen
Amgen

Leawood, Kansas, United States of America and 46 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3

AbbVie
AbbVie

Overland Park, Kansas, United States and 192 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems